ICRF-193 (C005B-025288)

General description

ICRF-193 is a bisdiopiperazine derivative. It inhibits topoisomerase II by forming a non-cleavable complex.

Application

ICRF-193 has been used as a topoisomerase II (TOP2) inhibitor to treat mouse oocytes to investigate the role of TOP2 in meiosis.

Biochem/physiol Actions

ICRF-193 helps in the enhancement of cell cycle without chromosome segregation. It is considered as an important drug for chemo-differentiation therapy against acute promyelocytic leukemia (APL). ICRF-193 serves as an inducer of differentiation between anticancer drugs.

ICRF-193 induces a G2 checkpoint that is associated with an ATR-dependent inhibition of polo-like kinase 1 (plk1) activity and a decrease in cyclin B1 phosphorylation. Induces apoptosis in several cell lines including K562 and Molt-4 cells.^, ICRF-193 is a topoisomerase II inhibitor, more potent against topoisomerase II-β than topoisomerase II-α, and may in addition cause DNA strand breaks.

Molecular Weight: 282.30. Empirical Formula: C₁₂H₁₈N₄O₄. biological source: synthetic (organic). Quality Level: 200. Assay: ≥. 95%. form: powder or flakes, solid. solubility: DMSO: 4 . mg/mL. storage temp.: −. 20°C. SMILES string: C[C@@H]([C@@H](C)N1CC(: O)NC(: O)C1)N2CC(: O)NC(: O)C2. InChI: 1S/C12H18N4O4/c1-7(15-3-9(17)13-10(18)4-15)8(2)16-5-11(19)14-12(20)6-16/h7-8H,3-6H2,1-2H3,(H,13,17,18)(H,14,19,20)/t7-,8+. InChI key: OBYGAPWKTPDTAS-OCAPTIKFSA-N. Pictograms: GHS06. Signal Word: Danger. Hazard Statements: H301 - H317. Precautionary Statements: P280 - P301 + P310 + P330 - P302 + P352. Hazard Classifications: Acute Tox. 3 Oral - Skin Sens. 1. Storage Class Code: 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable. Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Faceshields, Gloves.